Global Reach SMT operates diversified manufacturing facilities and serves customers across 80+ countries, enabling reliable multi-region supply for hospitals and distributors. This makes SMT an attractive partner for enterprise procurement programs, regional distribution agreements, and multi-site service contracts.

Evidence Driven Portfolio SMT's portfolio covers interventional cardiology and structural heart devices such as Hydra TAVR, Supraflex Cruz DES, and congenital occluders. Ongoing trial results and presentations at ESC and PCR London Valves build a strong clinical case for hospital adoption and accelerated tender success.

ESG Advantage ISO 50001:2018 energy management certification for SMT's Surat and Hyderabad facilities signals a strong ESG profile, appealing to healthcare buyers and public tenders that prioritize energy efficiency and sustainable supplier practices. Leverage this to differentiate SMT in competitive bids.

Growth IPO Readiness SMT's plan to go public with an IPO around Rs 1,500 crore indicates expansion of capacity and market reach, backed by private equity. This growth trajectory creates opportunities for larger, multi-year procurement commitments and strategic partnerships as SMT scales.

Strategic Alliances Leadership roles and active industry engagement, including the CEO's appointment as FICCI Medical Devices Committee Co-Chair and partnerships with HeartX, signal access to policy decision-makers and clinicians. Use these channels to pursue co-development, trial collaborations, and early engagement in RFPs.